In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Ixekizumab reduces erosion and increases backfill in the sacroiliac joints of patients with radiographic axial ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Discover the 7 warning signs of ulcerative colitis, plus breakthrough treatments and management strategies that can transform ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...